Endocyte Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates (Nasdaq:ECYT)
"March 22, 2012 (GLOBE NEWSWIRE) --
Endocyte, Inc. (Nasdaq:ECYT),
a biopharmaceutical company developing targeted small molecule drug
conjugates (SMDCs) and companion imaging diagnostics for personalized
therapy, today announced that the World Health Organization and the
United States Adopted Names (USAN) Council have approved the
nonproprietary name "vintafolide" (pronounced vin ta foe' lide) for Endocyte's therapeutic drug candidate EC145 and the nonproprietary name of "etarfolatide" (pronounced et" ar foe' la tide)
for Endocyte's companion imaging agent EC20. Vintafolide and
etarfolatide are currently being evaluated in the Phase 3 PROCEED trial
for the treatment of women with folate-receptor positive
platinum-resistant ovarian cancer. Etarfolatide is being used to select
patients with tumors that over-express folate receptors and who are most
likely to benefit from vintafolide therapy. Endocyte intends to file
European Marketing Authorisation Applications for both agents based on
positive Phase 2 results............."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.